Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis

Primary myelofibrosis is a form of myeloproliferative neoplasm characterized by stem-cell derived clonal proliferation, resulting in bone marrow fibrosis, splenomegaly and extramedullary haematopoiesis, with portal hypertension (PHT) occuring in 10%–20% of patients. Here, we report a patient with primary myelofibrosis whose PHT improved significantly following treatment with ruxolitinib, thereby allowing discontinuation of all drug therapy for PHT.

Source link

Related posts

The effect of prophylactic hemoclip placement and risk factors of delayed post-polypectomy bleeding in polyps sized 6 to 20 millimeters: a propensity score matching analysis


LSK BioPharma, Hengrui collaborate for trial of advanced HCC therapy


2009 to 2018 Saw Increase in Incidence of NAFLD in Children


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy